Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DNC4 | ISIN: CA4838092084 | Ticker-Symbol: N/A
1-Jahres-Chart
KANE BIOTECH INC Chart 1 Jahr
5-Tage-Chart
KANE BIOTECH INC 5-Tage-Chart

Aktuelle News zur KANE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiKane Biotech Inc (2): Kane Biotech sale of Stem Animal interest1
16.04.Kane Biotech Inc (2): Kane Biotech to hold webinar April 182
16.04.Kane Biotech Inc.: Kane Biotech to Host Investor Webinar1
15.04.Kane Biotech Inc (2): Kane Biotech closes STEM interest sale2
15.04.Kane Biotech Inc.: Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products484WINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) ("Kane") announces that, it has completed the sale of its interest in STEM Animal Health Inc. to...
► Artikel lesen
11.04.Kane Biotech to sell its STEM Animal Health for C$11.5 million1
11.04.Kane Biotech Inc (2): Kane Biotech signs agreement in principle for Stem sale1
11.04.Kane Biotech Inc (2): Kane Biotech to resume at 7:30 a.m. PT1
11.04.Kane Biotech Inc.: Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health210WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the "Company" or "Kane Biotech") announces today that it has reached an agreement in principle for...
► Artikel lesen
11.04.Kane Biotech Inc (2): Kane Biotech halted at the open1
26.03.Kane Biotech Inc (2): Kane Biotech loses $5.27-million in 20233
26.03.Kane Biotech Inc.: Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results174WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the "Company" or "Kane Biotech") today announces its fourth quarter and full year 2023 financial...
► Artikel lesen
20.03.Kane Biotech Inc (2): Kane extends exclusivity period on Stem offer1
20.03.Kane Biotech Inc.: Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health1
19.03.Kane Biotech Inc (2): Kane Biotech to release 2023 results March 261
19.03.Kane Biotech Inc.: Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 - Conference Call to Follow1
08.03.Kane Biotech Inc.: Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award1
22.02.Kane Biotech Inc (2): Kane Biotech appoints Huizinga as executive chair1
22.02.Kane Biotech Inc.: Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair162WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the "Company" or "Kane Biotech" or "Kane") announces that at the special meeting of the shareholders...
► Artikel lesen
31.01.Kane Biotech Inc (2): Kane Biotech files revyve wound gel spray patent1
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1